Clinical and genetic factors affecting tacrolimus trough levels and drug-related outcomes in Korean kidney transplant recipients

European Journal of Clinical Pharmacology

Volumn 68, Issue 5, 2012, Pages 657-669

  Kim, In Wha ^a   Moon, Yoo Jin ^a   Ji, Eunhee ^a   Kim, Kyung Im ^a   Han, Nayoung ^a   Kim, Sung Ju ^b   Shin, Wan Gyoon ^a   Ha, Jongwon ^c   Yoon, Jeong Hyun ^d   Lee, Hye Suk ^e   Oh, Jung Mi ^a  

^a Seoul National University   (South Korea)

^b Korea University   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

^d Pusan National University   (South Korea)

^e Seoul National University Hospital   (South Korea)

Author keywords

Kidney; Pharmacogenetics; Polymorphism; Tacrolimus; Transplantation

Indexed keywords

BASILIXIMAB; CREATININE; CYTOCHROME P450 3A5; GENOMIC DNA; METHYLPREDNISOLONE; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; AGE DISTRIBUTION; AGED; ALOPECIA; ARTICLE; BODY WEIGHT; CADAVER KIDNEY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXON; FEMALE; GASTROINTESTINAL SYMPTOM; GENETIC VARIABILITY; GENOTYPE; GRAFT RECIPIENT; HAIR LOSS; HEMATOCRIT; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PERSONALIZED MEDICINE; PHARMACOGENETICS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SOUTH KOREA; STATISTICAL MODEL; TREMOR;

ADULT; AGED; ALOPECIA; CALCINEURIN; CYTOCHROME P-450 CYP3A; DRUG MONITORING; FEMALE; GENETIC ASSOCIATION STUDIES; GRAFT REJECTION; HUMANS; HYPERLIPIDEMIAS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; TACROLIMUS; YOUNG ADULT;

EID: 84864281590     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-1182-5     Document Type: Article

References (41)

1. Kershner RP, Fitzsimmons WE (1996) Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation 62(7):920-926 (Pubitemid 26360352)
2. Laskow DA, Vincenti F, Neylan JF, Mendez R, Matas AJ (1996) An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. Transplantation 62(7):900-905 (Pubitemid 26360348)
3. Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, McMichael J, Lever J, Burckart G, Starzl T (1995) Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 29 (6):404-430 (Pubitemid 26004179)
4. Scott LJ, McKeage K, Keam SJ, Plosker GL (2003) Tacrolimus: a further update of its use in the management of organ transplantation. Drugs 63(12):1247-1297 (Pubitemid 36750952)
5. Venkataramanan R, Jain A, Warty VS, Abu-Elmagd K, Alessiani M, Lever J, Krajak A, Flowers J, Mehta S, Zuckerman S et al (1991) Pharmacokinetics of FK 506 in transplant patients. Transplant Proc 23(6):2736-2740
6. Nagase K, Iwasaki K, Nozaki K, Noda K (1994) Distribution and protein binding of FK506, a potent immunosuppressive macrolide lactone, in human blood and its uptake by erythrocytes. J Pharm Pharmacol 46(2):113-117 (Pubitemid 24070839)
7. Undre NA, van Hooff J, Christiaans M, Vanrenterghem Y, Donck J, Heeman U, Kohnle M, Zanker B, Land W, Morales JM, Andres A, Schafer A, Stevenson P (1999) Low systemic exposure to tacrolimus correlates with acute rejection. Transplant Proc 31(1-2):296-298 (Pubitemid 29127464)
8. Mourad M, Wallemacq P, De Meyer M, Brandt D, Van Kerkhove V, Malaise J, Chaib Eddour D, Lison D, Haufroid V (2006) The influence of genetic polymorphisms of cytochrome P450 3A5 and ABCB1 on starting dose- and weight-standardized tacrolimus trough concentrations after kidney transplantation in relation to renal function. Clin Chem Lab Med 44(10):1192-1198 (Pubitemid 44580800)
9. Kuypers DR, Claes K, Evenepoel P, Maes B, Coosemans W, Pirenne J, Vanrenterghem Y (2004) Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients. Clin Pharmacokinet 43(11):741-762 (Pubitemid 39159005)
10. Mourad M, Mourad G, Wallemacq P, Garrigue V, Van Bellingen C, Van Kerckhove V, De Meyer M, Malaise J, Eddour DC, Lison D, Squifflet JP, Haufroid V (2005) Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. Transplantation 80(7):977-984 (Pubitemid 41552896)
11. Christians U, Jacobsen W, Benet LZ, Lampen A (2002) Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 41(11):813-851
12. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T (1993) Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 268(9):6077-6080 (Pubitemid 23099291)
13. Hesselink DA, van Gelder T, van Schaik RH (2005) The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression? Pharmacogenomics 6(4):323-337 (Pubitemid 40916357)
14. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27(4):383-391 (Pubitemid 32268418)
15. MacPhee IA, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A, Goldberg L, Holt DW (2004) The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant 4(6):914-919 (Pubitemid 38745590)
16. Numakura K, Satoh S, Tsuchiya N, Horikawa Y, Inoue T, Kakinuma H, Matsuura S, Saito M, Tada H, Suzuki T, Habuchi T (2005) Clinical and genetic risk factors for posttransplant diabetes mellitus in adult renal transplant recipients treated with tacrolimus. Transplantation 80(10):1419-1424 (Pubitemid 41803623)
17. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97(7):3473-3478 (Pubitemid 30183327)
18. Anglicheau D, Flamant M, Schlageter MH, Martinez F, Cassinat B, Beaune P, Legendre C, Thervet E (2003) Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol Dial Transplant 18(11):2409-2414 (Pubitemid 37336834)
19. Haufroid V, Mourad M, Van Kerckhove V, Wawrzyniak J, De Meyer M, Eddour DC, Malaise J, Lison D, Squifflet JP, Wallemacq P (2004) The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 14(3):147-154 (Pubitemid 38373108)
20. Wang W, Zhang XD, Ma LL, Lu YP, Hu XP, Zhang P, Wang Y, Guan DL (2005) Relationship between MDR1 gene polymorphism and blood concentration of tacrolimus in renal transplant patients. Zhonghua Yi Xue Za Zhi 85(46):3277-3281 (Pubitemid 43173660)
21. Roy JN, Barama A, Poirier C, Vinet B, Roger M (2006) Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients. Pharmacogenet Genomics 16 (9):659-665 (Pubitemid 44223077)
22. Kuypers DR, de Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y (2007) CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther 82(6):711-725 (Pubitemid 350114816)
23. Hesselink DA, van Schaik RH, van Agteren M, de Fijter JW, Hartmann A, Zeier M, Budde K, Kuypers DR, Pisarski P, Le Meur Y, Mamelok RD, van Gelder T (2008) CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimustreated renal transplant recipients. Pharmacogenet Genomics 18 (4):339-348 (Pubitemid 351367527)
24. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130(6):461-470 (Pubitemid 29135798)
25. Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, Croker BP, Demetris AJ, Drachenberg CB, Fogo AB, Furness P, Gaber LW, Gibson IW, Glotz D, Goldberg JC, Grande J, Halloran PF, Hansen HE, Hartley B, Hayry PJ, Hill CM, Hoffman EO, Hunsicker LG, Lindblad AS, Yamaguchi Y et al (1999) The Banff 97 working classification of renal allograft pathology. Kidney Int 55(2):713-723 (Pubitemid 29082898)
26. Davidson J, Wilkinson A, Dantal J, Dotta F, Haller H, Hernandez D, Kasiske BL, Kiberd B, Krentz A, Legendre C, Marchetti P, Markell M, van der Woude FJ, Wheeler DC (2003) New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation 75(10 Suppl): SS3-SS24
27. Jun KR, Lee W, Jang MS, Chun S, Song GW, Park KT, Lee SG, Han DJ, Kang C, Cho DY, Kim JQ, Min WK (2009) Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea. Transplantation 87(8):1225-1231
28. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nuessler AC, Neuhaus P, Klattig J, Eiselt R, Koch I, Zibat A, Brockmoller J, Halpert JR, Zanger UM, Wojnowski L (2001) The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11(9):773-779 (Pubitemid 33151512)
29. Hesselink DA, van Gelder T, van Schaik RH, Balk AH, van der Heiden IP, van Dam T, van der Werf M, Weimar W, Mathot RA (2004) Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin Pharmacol Ther 76(6):545-556 (Pubitemid 39601545)
30. Barnieh L, Manns BJ, Klarenbach S, McLaughlin K, Yilmaz S, Hemmelgarn BR (2011) A description of the costs of living and standard criteria deceased donor kidney transplantation. Am J Transplant 11(3):478-488
31. Staatz C, Taylor P, Tett S (2001) Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation. Nephrol Dial Transplant 16(9):1905-1909 (Pubitemid 32821425)
32. Wynne HA, Cope LH, Mutch E, Rawlins MD, Woodhouse KW, James OF (1989) The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology 9(2):297-301 (Pubitemid 19063317)
33. Sotaniemi EA, Arranto AJ, Pelkonen O, Pasanen M (1997) Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther 61(3):331-339 (Pubitemid 27145435)
34. Wijnen RM, Ericzon BG, Tiebosch AT, Beysens AJ, Groth CG, Kootstra G (1991) Toxicity of FK 506 in the cynomolgus monkey: noncorrelation with FK 506 serum levels. Transplant Proc 23 (6):3101-3104
35. Shirbacheh MV, Jones JW, Harralson TA, Edelstein J, Tecimer T, Breidenbach WC, Jevans AW, Maldonado C, Barker JH, Gruber SA (1999) Pharmacokinetics of intra-arterial delivery of tacrolimus to vascularly isolated rabbit forelimb. J Pharmacol Exp Ther 289 (3):1196-1201 (Pubitemid 29246644)
36. Perrone RD, Madias NE, Levey AS (1992) Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 38(10):1933-1953
37. Leblond F, Guevin C, Demers C, Pellerin I, Gascon-Barre M, Pichette V (2001) Downregulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol 12(2):326-332 (Pubitemid 32116374)
38. Staatz CE, Tett SE (2005) Pharmacokinetic considerations relating to tacrolimus dosing in the elderly. Drugs Aging 22(7):541-557 (Pubitemid 41214548)
39. Fink J, Flasar M, Harrington J, Weir M, Bartlett S (1998) Alopecia totalis related to tacrolimus use following kidney and pancreas transplantation. [abstract presented at AST 1998]. 1998 [cited 2010 May 12 2010]; Available from: http://www.a-s-t.org/abstracts98/abs661.htm
40. Ichimaru N, Takahara S, Kokado Y, Wang JD, Hatori M, Kameoka H, Inoue T, Okuyama A (2001) Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. Atherosclerosis 158(2):417-423 (Pubitemid 32913652)
41. Yamauchi A, Ieiri I, Kataoka Y, Tanabe M, Nishizaki T, Oishi R, Higuchi S, Otsubo K, Sugimachi K (2002) Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation 74 (4):571-572